Trials / Withdrawn
WithdrawnNCT06682234
Study of Obeldesivir as Postexposure Prophylaxis for Filovirus Diseases Virus Disease
A Phase 2, Single-Arm Study of Obeldesivir for Postexposure Prophylaxis of Filovirus Diseases
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this clinical study is to learn more about the study drug, obeldesivir (ODV), and how safe and effective it is preventing Filovirus disease in participants with known or suspected exposure to Filovirus disease. The primary objective is to evaluate the safety and tolerability of ODV for Ebola virus (EBOV), Sudan virus (SUDV), and MARV postexposure prophylaxis (PEP).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | obeldesivir | Tablets administered orally |
Timeline
- Start date
- 2025-12-01
- Primary completion
- 2025-12-01
- Completion
- 2025-12-01
- First posted
- 2024-11-12
- Last updated
- 2026-03-20
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06682234. Inclusion in this directory is not an endorsement.